{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'expected to interfere with the evaluation of the assigned treatment (cemiplimab or IC of', 'chemotherapy), may be given at the discretion of the investigator.', 'Patients using immunosuppressive doses (>10 mg per day of prednisone or equivalent) of systemic', 'corticosteroids other than for corticosteroid replacement will not be eligible for the study. For', 'patients on the cemiplimab arm, it is recommended that patients do not receive systemic', 'corticosteroids such as hydrocortisone, prednisone, prednisolone (Solu-Medrol\u00ae) or', 'dexamethasone (Decadron) at any time throughout the study except in the case of a life-', 'threatening emergency and/or to treat an irAE.', 'NOTE: Bisphosphonates and denosumab are not prohibited.', '8.10.2.', 'Permitted Medications and Procedures', 'Physiologic replacement doses of systemic corticosteroids are permitted, even if >10 mg/day', 'prednisone equivalents. A brief course of corticosteroids for prophylaxis (eg, contrast dye allergy)', 'or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused', 'by contact allergen) is permitted.', 'NOTE: Bisphosphonates and denosumab are not prohibited.', 'Radiation therapy is not part of the study regimen in either the experimental group or the control', 'group. Patients for whom radiation therapy is planned are not eligible. If, during the course of the', 'study, a patient develops a symptomatic lesion for which palliative radiation therapy is deemed', 'appropriate by the investigator, this will be deemed PD, and generally, the patient would be', 'removed form study. Palliative radiation therapy may be allowed in certain circumstances in', 'patients who have been on study for at least 24 weeks. Palliative radiation is only allowed to a', 'non-target lesion in this study.', 'If the investigator feels that palliative radiation therapy to a non-target lesion, followed by', 'resumption of the assigned treatment (cemiplimab or IC of chemotherapy) after radiation is in the', 'best interest of the patient, such cases must be discussed with and approved by the medical monitor', 'prior to initiation of palliative radiation therapy. The patient will be deemed to have experienced', 'PD if radiation therapy is instituted, but will be followed for OS.', '9.', 'SAFETY DEFINITIONS, REPORTING, AND MONITORING', '9.1.', 'Obligations of Investigator', 'The investigator must promptly report to the Institutional Review Board (IRB)/Ethics Committee', '(EC) all unanticipated problems involving risks to patients according to local regulations.', '9.2.', 'Obligations of Sponsor', 'During the course of the study, the sponsor will report in an expedited manner all SAEs that are', 'both unexpected and at least reasonably related to the study drug (suspected unexpected serious', 'adverse reaction), to the health authorities, IRBs/ECs as appropriate, and to the investigators.', 'Any AE not listed as an expected event in the Reference Safety Information section of the', \"cemiplimab Investigator's Brochure or in the reference safety document for the IC chemotherapy\", 'Regeneron Pharmaceuticals, Inc.', 'Page 87 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '(United States Package Insert for pemetrexed, gemcitabine, vinorelbine, irinotecan, and topotecan)', 'will be considered as unexpected.', 'In addition, the sponsor will report all other SAEs to the health authorities, according to local', 'regulations.', 'At the completion of the study, the sponsor will report all safety observations made during the', 'conduct of the trial in the clinical study report to health authorities and IRB/EC as appropriate.', '9.3.', 'Definitions', '9.3.1.', 'Adverse Event', 'An AE is any untoward medical occurrence in a patient administered a study drug, which may or', 'may not have a causal relationship with the study drug. Therefore, an AE is any unfavorable and', 'unintended sign (including abnormal laboratory finding), symptom, or disease, which is', 'temporally associated with the use of a study drug, whether or not considered, related to the study', 'drug.', 'An AE also includes any worsening (ie, any clinically significant change in frequency and/or', 'intensity) of a pre-existing condition that is temporally associated with the use of the study drug.', 'Progression of underlying malignancy will not be considered an AE if it is clearly consistent with', 'the typical progression pattern of the underlying cancer (including time course, affected organs,', 'etc.). Similarly, death due to progression of malignancy will be considered a study endpoint but', 'not an AE. Clinical symptoms of progression may be reported as AEs if the symptom cannot be', 'determined as exclusively due to the progression of the underlying malignancy, or does not fit the', 'expected pattern of progression for the disease under study.', 'If there is any uncertainty about an AE being due only to progression of the underlying malignancy,', 'it should be reported as an AE or SAE as outlined in Section 9.4.', '9.3.2.', 'Serious Adverse Event', 'An SAE is any untoward medical occurrence that at any dose:', 'Results in death - includes all deaths, even those that appear to be completely unrelated', 'to study drug (eg, a car accident in which a patient is a passenger).', 'Is life-threatening - in the view of the investigator, the patient is at immediate risk of', 'death at the time of the event. This does not include an AE that had it occurred in a', 'more severe form, might have caused death.', 'Requires in-patient hospitalization or prolongation of existing hospitalization.', 'In-patient hospitalization is defined as admission to a hospital or an emergency room', 'for longer than 24 hours. Prolongation of existing hospitalization is defined as a', 'hospital stay that is longer than was originally anticipated for the event, or is prolonged', 'due to the development of a new AE as determined by the investigator or treating', 'physician.', 'Results in persistent or significant disability/incapacity (substantial disruption of', \"one's ability to conduct normal life functions).\", 'Regeneron Pharmaceuticals, Inc.', 'Page 88 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}